Disclosed herein are aryl boronic acids and boronate esters wherein the general formula and substituents are denoted in the specification their use in the treatment of FAAH mediated disease, disorder or conditions such as a painful syndrome , inflammatory disorder, an immune disorder, depression, anxiety, a sleep disorder, a feeding behaviour, a movement disorder, glaucoma, neuroprotection or cardiovascular disease and methods for their preparation involving a palladium catalysed reaction of a organohalide species and a organoboron species to form a boronate, followed by hydrolysis under aqueous acidic conditions or oxidative hydrolysis conditions, such as sodium periodate with ammonium acetate, to form a boronic acid. Exemplary compounds include: [5-(trifluoromethyl)biphen-3-yl]methylboronic acid 4-benzmidophenylboronic acid 4-(benzylsulfonyl)phenylboronic acid 4-(phenylthiomethyl)phenylboronic acid and 2-(benzyloxycarbonyl)-4-(3-fluorophenoxy)phenylboronic acid.
